Related Experiment Video
Updated: Sep 2, 2025

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
Published on: February 4, 2021
Autoimmune connective tissue diseases and aortic valve replacement outcomes: a population-based study
Mohamed M Gad1, Devora Lichtman1, Anas M Saad1
1Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Heart and Vascular Institute, 9500 Euclid Avenue, J2-3, Cleveland, OH 44195, USA.
Insights
Patients with autoimmune connective tissue diseases (CTDs) undergoing aortic valve replacement (AVR) have comparable outcomes to non-CTD patients. CTD history should be considered but not prohibit AVR interventions for valvular heart disease.
Area of Science:
- Cardiology
- Rheumatology
- Health Services Research
Background:
- Autoimmune connective tissue diseases (CTDs) are associated with a high burden of valvular heart disease.
- Patients with CTDs are often perceived as high surgical risk for interventions like aortic valve replacement (AVR).
Purpose of the Study:
- To compare the outcomes of aortic valve replacement (AVR) in patients with and without connective tissue diseases (CTDs).
- To evaluate the impact of CTD on mortality and stroke after AVR.
Main Methods:
- Retrospective analysis of the Nationwide Readmissions Database (2012-2018).
- Inclusion of patients undergoing AVR, with specific CTDs identified (e.g., lupus, rheumatoid arthritis, scleroderma).
- Exclusion of patients undergoing concomitant coronary artery bypass grafting.
Main Results:
- A total of 569,600 hospitalizations were analyzed, with 16,531 (2.9%) having CTD.
- CTD patients were more likely female, with higher rates of heart failure and pulmonary hypertension.
- CTD patients exhibited lower mortality (OR 0.66) and stroke (OR 0.87) rates compared to non-CTD patients post-AVR.
- Both surgical AVR (SAVR) and transcatheter AVR (TAVR) showed lower mortality in CTD patients; stroke outcomes were comparable for TAVR.
Conclusions:
- Outcomes for patients with CTDs undergoing AVR are not inferior to those without CTDs.
- A history of CTD should be considered in heart team decision-making for AVR but should not preclude intervention.
- These findings support AVR interventions for carefully selected CTD patients with valvular heart disease.
Aims:
Patients with autoimmune connective tissue diseases (CTDs) have a high burden of valvular heart disease and are often thought of as high surgical risk patients.
Methods And Results:
Patients undergoing aortic valve replacement (AVR) were identified in the Nationwide Readmissions Database between January 2012 and December 2018. Patients with a history of systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, mixed C, Sjögren syndrome, polymyositis, and dermatomyositis were included in the CTD cohort. Patients undergoing coronary artery bypass grafting concomitantly with AVR were excluded. A total of 569 600 hospitalizations were included, of which16 531 (2.9%) had CTD. CTD patients were more likely to be females, with higher rates of heart failure, pulmonary hypertension, and more likely to be insured by Medicare. CTD patients had lower mortality than non-CTD patients [odds ratio (OR) 0.66; 95% confidence interval (CI): 0.59-0.74] and stroke [OR 0.87; 95% (CI): 0.79-0.97]. CTD patients undergoing SAVR had lower mortality [OR 0.69; 95% (CI): 0.60-0.80] and stroke [OR 0.86; 95% (CI): 0.75-0.98). CTD patients undergoing TAVR had lower mortality outcomes [OR 0.67; 95% (CI): 0.56-0.80]; however, they had comparable stroke outcomes [OR 0.97; 95% (CI): 0.83-1.13, P = 0.69].
Conclusions:
Outcomes for patients with CTD requiring AVR are not inferior to their non-CTD counterparts. A comprehensive heart team selection of patients undergoing AVR approaches should place CTD history under consideration; however, pre-existing CTD should not be prohibitive of AVR interventions.
Related Concept Videos
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Aortic Regurgitation I: Introduction
Aortic Regurgitation III: Medical Management
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

